X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse AMAR REMEDIES with THE PROCTER & GAMBLE CO. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AMAR REMEDIES vs P&G (US) - Comparison Results

P&G (US)
   Change

Procter & Gamble Company (P&G) is an American multinational consumer goods company headquartered in the United States. The company was incorporated in Ohio in 1905, having been built from a business founded in 1837 by William Procter and James Gamble... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 AMAR REMEDIES   P&G
EQUITY SHARE DATA
    AMAR REMEDIES
Jun-12
P&G
Jun-14
AMAR REMEDIES/
P&G
5-Yr Chart
Click to enlarge
High Rs1645,480-   
Low Rs864,701-   
Sales per share (Unadj.) Rs261.61,930.2-  
Earnings per share (Unadj.) Rs17.4270.6-  
Cash flow per share (Unadj.) Rs22.3343.6-  
Dividends per share (Unadj.) Rs0156.46-  
Dividend yield (eoy) %03.1 0.0%  
Book value per share (Unadj.) Rs100.71,608.4-  
Shares outstanding (eoy) m26.162,748.03-   
Bonus/Rights/Conversions -BB, ESOP-  
Price / Sales ratio x0.52.6 18.1%   
Avg P/E ratio x7.218.8 38.2%  
P/CF ratio (eoy) x5.614.8 37.9%  
Price / Book Value ratio x1.23.2 39.2%  
Dividend payout %057.8 0.0%   
Avg Mkt Cap Rs m3,27013,989,121 0.0%   
No. of employees `000NA118.0 0.0%   
Total wages/salary Rs m1630-   
Avg. sales/employee Rs ThNM44,952.0-  
Avg. wages/employee Rs ThNM0-  
Avg. net profit/employee Rs ThNM6,301.0-  
INCOME DATA
Net Sales Rs m6,8445,304,339 0.1%  
Other income Rs m2119,541 0.1%   
Total revenues Rs m6,8655,323,880 0.1%   
Gross profit Rs m1,1311,181,857 0.1%  
Depreciation Rs m128200,584 0.1%   
Interest Rs m39845,277 0.9%   
Profit before tax Rs m626955,537 0.1%   
Minority Interest Rs m0-9,068 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-500-   
Tax Rs m121202,947 0.1%   
Profit after tax Rs m455743,522 0.1%  
Gross profit margin %16.522.3 74.2%  
Effective tax rate %19.321.2 91.0%   
Net profit margin %6.614.0 47.4%  
BALANCE SHEET DATA
Current assets Rs m4,9042,019,062 0.2%   
Current liabilities Rs m3,5812,153,742 0.2%   
Net working cap to sales %19.3-2.5 -761.3%  
Current ratio x1.40.9 146.1%  
Inventory Days Days12430 418.4%  
Debtors Days Days10028 356.9%  
Net fixed assets Rs m1,6891,424,333 0.1%   
Share capital Rs m262326,963 0.1%   
"Free" reserves Rs m2,3580-   
Net worth Rs m2,6354,420,006 0.1%   
Long term debt Rs m5071,265,130 0.0%   
Total assets Rs m6,8629,143,092 0.1%  
Interest coverage x2.622.1 11.6%   
Debt to equity ratio x0.20.3 67.2%  
Sales to assets ratio x1.00.6 171.9%   
Return on assets %12.48.6 144.1%  
Return on equity %17.316.8 102.7%  
Return on capital %31.017.4 177.7%  
Exports to sales %4.00-   
Imports to sales %00-   
Net fx Rs m2710-   
CASH FLOW
From Operations Rs m-313891,358 -0.0%  
From Investments Rs m-489-262,273 0.2%  
From Financial Activity Rs m769-464,837 -0.2%  
Net Cashflow Rs m-33164,248 -0.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for P&G (US) is United States Dollars. All data has been converted at 63.86 Rs / USD

Compare AMAR REMEDIES With: UNILEVER PLC. (UK)  HYPERMARCAS (Brazil)  

Compare AMAR REMEDIES With: BATA INDIA  JYOTHY LABS  HIND. UNILEVER  COLGATE  KARUTURI GLOBAL  



Today's Market

Of Sensex Touching Record Highs, Rally in Banking Stocks and Key Stocks in Action Today(Pre-Open)

BSE Sensex is on a roll. The index touched a record high of 35,000 on Wednesday and further inched upwards to end yesterday's trade at a level of 35,260.

Related Views On News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AMAR REMEDIES SHARE PRICE


Dec 11, 2013 (Close)

TRACK AMAR REMEDIES

  • Track your investment in AMAR REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AMAR REMEDIES 8-QTR ANALYSIS

COMPARE AMAR REMEDIES WITH

MARKET STATS